Anthem Biosciences Limited
Founded in 2006, Anthem Biosciences Ltd provides integrated CRDMO services and specializes in manufacturing specialty ingredients, focusing on both New Chemical Entities and New Biological Entities, with platforms like RNA interference and Antibody-Drug Conjugates.
What Anthem files
- Others29
- Investor Meet18
- Updates11
- Important6
- PPTs5
- Board Meeting4
Anthem Biosciences has successfully settled the upside sharing arrangement of approximately 127.68 Cr arising from the divestment by Viridity Tone LLP, fulfilling the terms approved by public shareholders and distributing the amount to the designated principal shareholders.
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Cr, down 22.6% YoY due to delivery timing shifts. EBITDA was ₹175.5 Cr (39.6% margin) and PAT ₹119.9 Cr (27.1% margin). Management expects strong H2FY27 deliveries and sustained industry-leading margins.
Anthem reports Q1FY27 consolidated revenue of ₹418.2 Cr, EBITDA ₹175.5 Cr (39.6% margins), and PAT ₹119.9 Cr (27.1% margins). Management notes Q1 reflects delivery timing shifts; strong demand and higher deliveries are expected in H2, sustaining revenue growth and industry-leading margins.
Anthem Biosciences reported a strong quarter, with Q4 revenue hitting a record ₹610.9 Cr (up 26% YoY). FY26 consolidated revenue reached ₹2,124.3 Cr, and PAT surged over 30% to ₹591.8 Cr. Robust CRDMO growth and healthy cash position signal strong future prospects.
Anthem Biosciences posted robust FY26 results. FY26 revenue grew 15.2% to ₹2,124.3 Cr, with PAT up 31.1% to ₹591.8 Cr. Q4 revenue jumped 26.4% to ₹610.9 Cr, and PAT surged 129.8% to ₹189.8 Cr. Strong CRDMO performance.